Beam Therapeutics Inc BEAM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
24.75quote price arrow up+0.13 (+0.53%)
Volume
185,950
Close
24.62quote price arrow up+0.83 (+3.49%)
Volume
1,144,342
52 week range
16.95 - 49.50
Loading...
  • Open23.76
  • Day High24.86
  • Day Low23.24
  • Prev Close23.79
  • 52 Week High49.50
  • 52 Week High Date02/27/24
  • 52 Week Low16.95
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap2.026B
  • Shares Out82.31M
  • 10 Day Average Volume1.18M
  • Dividend-
  • Dividend Yield-
  • Beta1.88
  • YTD % Change-9.55

KEY STATS

  • Open23.76
  • Day High24.86
  • Day Low23.24
  • Prev Close23.79
  • 52 Week High49.50
  • 52 Week High Date02/27/24
  • 52 Week Low16.95
  • 52 Week Low Date10/23/23
  • Market Cap2.026B
  • Shares Out82.31M
  • 10 Day Average Volume1.18M
  • Dividend-
  • Dividend Yield-
  • Beta1.88
  • YTD % Change-9.55

RATIOS/PROFITABILITY

  • EPS (TTM)-1.74
  • P/E (TTM)-14.13
  • Fwd P/E (NTM)-4.95
  • EBITDA (TTM)-160.893M
  • ROE (TTM)-16.09%
  • Revenue (TTM)360.911M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-37.33%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beam Therapeutics Inc

 

Profile

MORE
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it...
John Evans
Chief Executive Officer, Director
Giuseppe Ciaramella Ph.D.
President
Terry-Ann Burrell
Chief Financial Officer, Treasurer
Address
238 Main Street
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
VCYT
Veracyte Inc
22.88-0.52-2.22%
PTGX
Protagonist Therapeutics Inc
30.74-1.20-3.76%
CPRX
Catalyst Pharmaceuticals Inc
16.49+0.09+0.55%
ZLAB
Zai Lab Ltd
19.40-0.53-2.66%
KNSA
Kiniksa Pharmaceuticals Ltd
19.77-0.34-1.69%